Search Results - "Clinical drug investigation"

Refine Results
  1. 1

    Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review by Plantone, Domenico, Koudriavtseva, Tatiana

    Published in Clinical drug investigation (01-08-2018)
    “…The process of finding new therapeutic indications for currently used drugs, defined as ‘repurposing’, is receiving growing attention. Chloroquine and…”
    Get full text
    Journal Article
  2. 2

    Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia by Zhang, Shengyu, Li, Lei, Shen, Aizong, Chen, Yongwu, Qi, Zhigang

    Published in Clinical drug investigation (01-06-2020)
    “…Since December 2019, a novel coronavirus pneumonia (COVID-19) has broken out in Wuhan, China and spread rapidly. Recent studies have found that ⁓ 15.7% of…”
    Get full text
    Journal Article
  3. 3

    The Safety of Melatonin in Humans by Andersen, Lars Peter Holst, Gögenur, Ismail, Rosenberg, Jacob, Reiter, Russel J.

    Published in Clinical drug investigation (01-03-2016)
    “…Exogenous melatonin has been investigated as treatment for a number of medical and surgical diseases, demonstrating encouraging results. The aim of this review…”
    Get full text
    Journal Article
  4. 4

    Azithromycin for COVID-19: More Than Just an Antimicrobial? by Bleyzac, Nathalie, Goutelle, Sylvain, Bourguignon, Laurent, Tod, Michel

    Published in Clinical drug investigation (01-08-2020)
    “…Most of them evaluate established antiviral drugs such as lopinavir/ritonavir, and chloroquine (CQ) or its derivative hydroxychloroquine (HCQ), which have…”
    Get full text
    Journal Article
  5. 5

    An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19) by Das, Saibal, Bhowmick, Subhrojyoti, Tiwari, Sayali, Sen, Sukanta

    Published in Clinical drug investigation (01-07-2020)
    “…Background and Objective The world is currently experiencing the Coronavirus Disease-19 (COVID-19) pandemic. There is no approved drug for the definitive…”
    Get full text
    Journal Article
  6. 6

    Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS by Ji, Huan-huan, Tang, Xue-wen, Dong, Zhi, Song, Lin, Jia, Yun-tao

    Published in Clinical drug investigation (01-03-2019)
    “…Background and Objective Immune checkpoint inhibitors (ICIs)—cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death receptor-1 (PD-1) monoclonal…”
    Get full text
    Journal Article
  7. 7

    Management of Left Ventricular Thrombi with Direct Oral Anticoagulants: Retrospective Comparative Study with Vitamin K Antagonists by Daher, Jessica, Da Costa, Antoine, Hilaire, Christophe, Ferreira, Thomas, Pierrard, Romain, Guichard, Jean Baptiste, Romeyer, Cécile, Isaaz, Karl

    Published in Clinical drug investigation (01-04-2020)
    “…Background and Objectives The efficacy of direct oral anticoagulants (DOACs) in the management of left ventricular (LV) thrombi remains to be determined,…”
    Get full text
    Journal Article
  8. 8

    Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study by Pirro, Federico, Caldarola, Giacomo, Chiricozzi, Andrea, Burlando, Martina, Mariani, Marco, Parodi, Aurora, Peris, Ketty, De Simone, Clara

    Published in Clinical drug investigation (01-10-2021)
    “…Background The efficacy of biological therapies used for the treatment of chronic plaque psoriasis can be influenced by numerous variables including  body mass…”
    Get full text
    Journal Article
  9. 9

    The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder by De Aquino, Joao P., Parida, Suprit, Sofuoglu, Mehmet

    Published in Clinical drug investigation (01-05-2021)
    “…Although expanding the availability of buprenorphine—a first-line pharmacotherapy for opioid-use disorder (OUD)—has increased the capacity of healthcare…”
    Get full text
    Journal Article
  10. 10

    Riboflavin in Neurological Diseases: A Narrative Review by Plantone, Domenico, Pardini, Matteo, Rinaldi, Giuseppe

    Published in Clinical drug investigation (01-06-2021)
    “…Riboflavin is classified as one of the water-soluble B vitamins. It is part of the functional group of flavin mononucleotide (FMN) and flavin adenine…”
    Get full text
    Journal Article
  11. 11
  12. 12

    Gut Microbiome in Psoriasis is Perturbed Differently During Secukinumab and Ustekinumab Therapy and Associated with Response to Treatment by Yeh, Nai-Lun, Hsu, Che-Yuan, Tsai, Tsen-Fang, Chiu, Hsien-Yi

    Published in Clinical drug investigation (01-12-2019)
    “…Background and Objective Immunotherapy could change the complex host-microbial interactions. We aimed to investigate the dynamics of gut microbiome in response…”
    Get full text
    Journal Article
  13. 13

    Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings by Koshimichi, Hiroki, Ishibashi, Toru, Kawaguchi, Nao, Sato, Chisako, Kawasaki, Akira, Wajima, Toshihiro

    Published in Clinical drug investigation (01-12-2018)
    “…Background and Objective Baloxavir marboxil, a prodrug that is metabolized to baloxavir acid, suppresses viral replication by inhibiting cap-dependent…”
    Get full text
    Journal Article
  14. 14

    Lecanemab: More Questions Than Answers by Kaur, Upinder, Reddy, Jaideep, Tiwari, Ashutosh, Chakrabarti, Sasanka, Chakrabarti, Sankha Shubhra

    Published in Clinical drug investigation (2024)
    “…The approval of lecanemab by the US Food and Drug Administration has been touted as a defining moment in the treatment of Alzheimer’s disease. Lecanemab, an…”
    Get full text
    Journal Article
  15. 15

    Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features by Lyseng-Williamson, Katherine A

    Published in Clinical drug investigation (01-08-2019)
    “…Glucagon-like peptide-1 receptor analogues/agonists (GLP-1RAs) are well established as effective adjuncts to lifestyle modification in the treatment of type 2…”
    Get full text
    Journal Article
  16. 16

    Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects by Rognoni, Carla, Bertolani, Arianna, Jommi, Claudio

    Published in Clinical drug investigation (01-04-2021)
    “…Background and Objectives Second-generation antipsychotics (SGAs) for schizophrenia show different risk profiles, whose evidence has been evaluated through…”
    Get full text
    Journal Article
  17. 17

    Real-Life Experience of Tralokinumab for the Treatment of Adult Patients with Severe Atopic Dermatitis: A Multicentric Prospective Study by De Greef, Axel, Ghislain, Pierre-Dominique, Bulinckx, Audrey, Coster, Alison, de Halleux, Céline, Damsin, Thomas, Jacobs, Marie-Claude, Suys, Erwin, Zoghaib, Samer, Baeck, Marie

    Published in Clinical drug investigation (01-04-2023)
    “…Background Tralokinumab, the first fully human monoclonal antibody that binds specifically to interleukin-13, was safe and effective for treating atopic…”
    Get full text
    Journal Article
  18. 18

    The Respimat® Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients by Iwanaga, Takashi, Tohda, Yuji, Nakamura, Shuhei, Suga, Yasunori

    Published in Clinical drug investigation (01-11-2019)
    “…Successful treatment for respiratory diseases relies on effective delivery of medication to the lungs using an inhalation device. Different inhalers have…”
    Get full text
    Journal Article
  19. 19

    Paxlovid-Tacrolimus Drug–Drug Interaction in a 23-Year-Old Female Kidney Transplant Patient with COVID-19 by Berar Yanay, Noa, Bogner, Ido, Saker, Khader, Tannous, Elias

    Published in Clinical drug investigation (01-08-2022)
    “…Kidney transplant patients are at a high risk for adverse severe acute respiratory syndrome coronavirus 2 (SARSCOV-2) infection outcomes in terms of morbidity…”
    Get full text
    Journal Article
  20. 20

    Cannabidiol in the Treatment of Epilepsy by von Wrede, Randi, Helmstaedter, Christoph, Surges, Rainer

    Published in Clinical drug investigation (01-03-2021)
    “…Anecdotal reports addressing the successful seizure treatment of severe epilepsies with cannabidiol (CBD) have increased both public interest and academic…”
    Get full text
    Journal Article